Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Robert Scheinman to Complement Activation

This is a "connection" page, showing publications Robert Scheinman has written about Complement Activation.

 
Connection Strength
 
 
 
0.883
 
  1. Banda NK, Moreland LW, Deane KD, Simberg D, Scheinman RI, Frank RM, Seifert JA, Lau R, Pitzalis C, Lewis MJ, Holers VM. Analysis of human factor H-related gene and protein expressed in rheumatoid arthritis synovium identifies a novel mechanism promoting dysregulated complement pathway activation. Sci Rep. 2025 Jun 04; 15(1):19633.
    View in: PubMed
    Score: 0.187
  2. Li Y, Saba L, Scheinman RI, Banda NK, Holers M, Monte A, Dylla L, Moghimi SM, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano. 2024 10 22; 18(42):28649-28658.
    View in: PubMed
    Score: 0.179
  3. Li Y, Wang G, Griffin L, Banda NK, Saba LM, Groman EV, Scheinman R, Moghimi SM, Simberg D. Complement opsonization of nanoparticles: Differences between humans and preclinical species. J Control Release. 2021 10 10; 338:548-556.
    View in: PubMed
    Score: 0.144
  4. Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
    View in: PubMed
    Score: 0.135
  5. Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release. 2019 05 28; 302:181-189.
    View in: PubMed
    Score: 0.122
  6. Li Y, Jacques S, Gaikwad H, Nebbia M, Banda NK, Holers VM, Tomlinson SA, Scheinman RI, Monte A, Saba L, Lasda E, Hasselberth J, Busquet N, Zelek WM, Moghimi SM, Simberg D. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Sci Adv. 2025 Jul 11; 11(28):eadw1731.
    View in: PubMed
    Score: 0.047
  7. Li Y, Jacques S, Gaikwad H, Wang G, Banda NK, Holers VM, Scheinman RI, Tomlinson S, Moghimi SM, Simberg D. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat Nanotechnol. 2024 Feb; 19(2):246-254.
    View in: PubMed
    Score: 0.042
  8. Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Bioconjug Chem. 2017 11 15; 28(11):2747-2755.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)